Erlotinib pretreatment improves photodynamic therapy of non-small cell lung carcinoma xenografts via multiple mechanisms

Cancer Research

Volumn 75, Issue 15, 2015, Pages 3118-3126

  Gallagher Colombo, Shannon M ^a   Miller, Joann ^a   Cengel, Keith A ^a   Putt, Mary E ^b   Vinogradov, Sergei A ^b   Busch, Theresa M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; VASCULOTROPIN; VERTEPORFIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING; FEMALE; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MICE, NUDE; PHOTOCHEMOTHERAPY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942847900     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3304     Document Type: Article

References (50)

1. Robinson KW, Sandler AB EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. Curr Oncol Rep 2013; 15: 396-404.
2. Baker SJ, Reddy EP Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010; 77: 573-86.
3. Viloria-Petit A.M., Kerbel RS Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004; 58: 914-26.
4. Weyergang A, Kaalhus O, Berg K. Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478. Photochem Photobiol Sci 2008; 7: 1032-40.
5. Weyergang A, Selbo PK, Berg K. Sustained ERK[corrected] inhibition by EGFR targeting therapies isapredictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy. Biochim Biophys Acta 2013; 1830: 2659-70.
6. Gijsens A, Missiaen L, Merlevede W., de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 2000; 60: 2197-202.
7. del Carmen M.G., Rizvi I, Chang Y., Moor AC, Oliva E, Sherwood M, et al Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005; 97: 1516-24.
8. Bhuvaneswari R, Gan YY, Soo K.C., Olivo M. Targeting EGFR with photo-dynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8: 94.
9. Koon HK, Chan PS, Wong R.N., Wu ZG, Lung ML, Chang CK, et al Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem 2009; 108: 1356-63.
10. Postiglione I, Chiaviello A, Aloj S.M., Palumbo G. 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy. Cell Prolif 2013; 46: 382-95.
11. Esipova TV, Karagodov A, Miller J., Wilson DF, Busch TM, Vinogradov SA. Two new "protected" oxyphors for biological oximetry: properties and application in tumor imaging. Anal Chem 2011; 83: 8756-65.
12. Edmonds C, Hagan S, Gallagher-Colombo SM, Busch T.M., Cengel KA. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer Biol Ther 2012; 13: 1463-70.
13. Cerniglia GJ, Pore N, Tsai J.H., Schultz S., Mick R, Choe R, et al Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009; 4: e6539.
14. He C, Agharkar P, Chen B. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy. Pharm Res 2008; 25: 1873-80.
15. Lu YY, Jing DD, Xu M, Wu K., Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14: 5403-11.
16. Gallagher-Colombo S.M., Maas AL, Yuan M, Busch TM Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response. Isr J Chem 2012; 52: 681-90.
17. Bhuvaneswari R, Thong PS, Gan Y.Y., Soo KC, Olivo M. Evaluation of hypericin-mediated photodynamic therapy in combination with angio-genesis inhibitor bevacizumab using in vivo fluorescence confocal endo-microscopy. J Biomed Opt 2010; 15: 011114.
18. Gomer CJ. Induction of prosurvival molecules during treatment: rethinking therapy options for photodynamic therapy. J Natl Compr Canc Netw 2012; 10(Suppl 2): S35-9.
19. Liu W, Baer MR, Bowman M.J., Pera P., Zheng X, Morgan J, et al The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007; 13: 2463-70.
20. Iacovelli R, Palazzo A, Procopio G., Santoni M, Trenta P, De Benedetto A, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2014; 77: 929-38.
21. Zhou C, Wu YL, Chen G, Feng J., Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
22. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42: 547-57.
23. Mok TS, Lee K, Leung L. Targeting epidermal growth factor receptor in the management of lung cancer. Semin Oncol 2014; 41: 101-9.
24. Padda SK, Burt BM, Trakul N, Wakelee HA Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol 2014; 41: 40-56.
25. Ausborn NL, Le QT, Bradley J.D., Choy H., Dicker AP, Saha D, et al. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2012; 83: e453-64.
26. Gomer CJ, Ferrario A, Luna M., Rucker N, Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 2006; 38: 516-21.
27. Martinez-Carpio P.A., Trelles MA The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med Sci 2010; 25: 767-71.
28. Hasan T. Using cellular mechanisms to develop effective combinations of photodynamic therapy and targeted therapies. J Natl Compr Canc Netw 2012; 10(suppl 2):S23-6.
29. Mir Y, Elrington SA, Hasan T. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nano-medicine 2013; 9: 1114-22.
30. Zhang FL, Huang Q, Zheng K., Li J, Liu JY, Xue JP A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib. Chem Commun 2013; 49: 9570-2.
31. Abu-Yousif A.O., Moor AC, Zheng X, Savellano M.D., Yu W., Selbo PK, et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett 2012; 321: 120-7.
32. Rizvi I, Dinh TA, Yu W, Chang Y., Sherwood ME, Hasan T. Photoimmu-notherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. Isr J Chem 2012; 52: 776-87.
33. Spring BQ, Abu-Yousif AO, Palanisami A., Rizvi I, Zheng X, Mai Z., et al. Selective treatment and monitoring of disseminated cancer micrometas-tases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014; 111: e933-42.
34. Soukos NS, Hamblin MR, Keel S, Fabian R.L., Deutsch TF, Hasan T. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 2001; 61: 4490-6.
35. Zou Y, Ling YH, Sironi J, Schwartz E.L., Perez-Soler R, Piperdi B. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol 2013; 8: 693-702.
36. Higgins B, Kolinsky K, Smith M., Beck G, Rashed M, Adames V., et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004; 15: 503-12.
37. Maas AL, Carter SL, Wileyto EP, Miller J, Yuan M, Yu G, et al. Tumor vascular microenvironment determines responsiveness to photodynamic therapy. Cancer Res 2012; 72: 2079-88.
38. Chen B, Pogue BW, Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 2006; 16: 279-305.
39. Fingar VH, Kik PK, Haydon P.S., Cerrito PB, Tseng M, Abang E, et al Analysis of acute vascular damage after photodynamic therapy using benzopor-phyrin derivative (BPD). Br J Cancer 1999; 79: 1702-8.
40. Major A, Kimel S, Mee S., Milner TE, Smithies DJ, Srinivas SM, et al Microvascular photodynamic therapy effects determined in vitro using optical doppler tomography. IEEE J Sel Top Quantum Electron 1999; 5: 1168-75.
41. Chen B, Pogue BW, Goodwin I.A., O'Hara JA, Wilmot CM, Hutchins J.E., et al. Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res 2003; 160: 452-9.
42. Pogue BW, O'Hara JA, Demidenko E, Wilmot C.M., Goodwin IA, Chen B, et al. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res 2003; 63: 1025-33.
43. Naumov GN, Nilsson MB, Cascone T, Briggs A., Straume O, Akslen LA, et al Combined vascular endothelial growth factor receptor and epidermal growthfactor receptor(EGFR)blockade in hibitstumor growthinxenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15: 3484-94.
44. Baker CH, Pino MS, Fidler IJ Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neo-plasia 2006; 8: 470-6.
45. Qayum N, Muschel RJ, Im J.H., Balathasan L., Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69: 6347-54.
46. Weiss A, Bonvin D, Berndsen R.H., Scherrer E., Wong TJ, Dyson PJ, et al. Angiostatic treatment prior to chemo-or photodynamic therapy improves anti-tumor efficacy. Sci Rep 2015; 5: 8990.
47. Bhuvaneswari R, Yuen GY, Chee S.K., Olivo M. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers Surg Med 2011; 43: 651-62.
48. Bhuvaneswari R, Yuen GY, Chee S.K., Olivo M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem Photobiol Sci 2007; 6: 1275-83.
49. Chen X, Liu Y, Roe O.D., Qian Y., Guo R, Zhu L, et al Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One 2013; 8: e59314.
50. Chong CR, Janne PA The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19: 1389-400.